BioPharma Dive October 25, 2024
The British pharma is making what it calls its largest U.S. manufacturing investment. Meanwhile, Amgen’s competition to Regeneron’s blockbuster isn’t all that low cost.
Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed.
Amgen set a list price of $1,665 per shot for its biosimilar version of Regeneron’s Eylea, a 10% discount from the eye drug’s current wholesale cost, RBC analyst Brian Abrahams wrote in an Oct. 25 note to clients. On Tuesday, Amgen said it would launch its biosimilar, branded Pavblu, without a legal settlement with Regeneron following a court decision that lifted a temporary injunction on its launch. Such “at risk” launches...
Today's Sponsors
Today's Sponsor